nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—ABCB1—peripheral nervous system neoplasm	0.474	1	CbGaD
Tolvaptan—ABCB1—Alitretinoin—peripheral nervous system neoplasm	0.0568	0.167	CbGbCtD
Tolvaptan—ABCB1—Topotecan—peripheral nervous system neoplasm	0.0568	0.167	CbGbCtD
Tolvaptan—ABCB1—Dactinomycin—peripheral nervous system neoplasm	0.0394	0.116	CbGbCtD
Tolvaptan—CYP3A4—Topotecan—peripheral nervous system neoplasm	0.034	0.1	CbGbCtD
Tolvaptan—CYP3A4—Tretinoin—peripheral nervous system neoplasm	0.0316	0.0931	CbGbCtD
Tolvaptan—ABCB1—Vincristine—peripheral nervous system neoplasm	0.0242	0.0714	CbGbCtD
Tolvaptan—ABCB1—Cisplatin—peripheral nervous system neoplasm	0.0226	0.0666	CbGbCtD
Tolvaptan—ABCB1—Etoposide—peripheral nervous system neoplasm	0.0222	0.0654	CbGbCtD
Tolvaptan—ABCB1—Doxorubicin—peripheral nervous system neoplasm	0.0152	0.0446	CbGbCtD
Tolvaptan—CYP3A4—Vincristine—peripheral nervous system neoplasm	0.0145	0.0428	CbGbCtD
Tolvaptan—CYP3A4—Etoposide—peripheral nervous system neoplasm	0.0133	0.0392	CbGbCtD
Tolvaptan—CYP3A4—Doxorubicin—peripheral nervous system neoplasm	0.00908	0.0267	CbGbCtD
Tolvaptan—AVPR2—Arf6 trafficking events—NME1—peripheral nervous system neoplasm	0.00141	0.103	CbGpPWpGaD
Tolvaptan—AVPR2—Vasopressin regulates renal water homeostasis via Aquaporins—GNAS—peripheral nervous system neoplasm	0.000619	0.0453	CbGpPWpGaD
Tolvaptan—AVPR2—Aquaporin-mediated transport—GNAS—peripheral nervous system neoplasm	0.00054	0.0395	CbGpPWpGaD
Tolvaptan—AVPR2—G alpha (s) signalling events—VIP—peripheral nervous system neoplasm	0.000512	0.0375	CbGpPWpGaD
Tolvaptan—AVPR1A—G alpha (q) signalling events—NTS—peripheral nervous system neoplasm	0.000489	0.0358	CbGpPWpGaD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.000483	0.0354	CbGpPWpGaD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—NTS—peripheral nervous system neoplasm	0.00048	0.0351	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—NTS—peripheral nervous system neoplasm	0.000438	0.0321	CbGpPWpGaD
Tolvaptan—Blood uric acid increased—Epirubicin—peripheral nervous system neoplasm	0.000394	0.00228	CcSEcCtD
Tolvaptan—Anorexia—Melphalan—peripheral nervous system neoplasm	0.000392	0.00227	CcSEcCtD
Tolvaptan—Angiopathy—Vincristine—peripheral nervous system neoplasm	0.000388	0.00225	CcSEcCtD
Tolvaptan—Pulmonary embolism—Epirubicin—peripheral nervous system neoplasm	0.000387	0.00224	CcSEcCtD
Tolvaptan—Ill-defined disorder—Dactinomycin—peripheral nervous system neoplasm	0.000387	0.00224	CcSEcCtD
Tolvaptan—Malnutrition—Alitretinoin—peripheral nervous system neoplasm	0.000387	0.00224	CcSEcCtD
Tolvaptan—Hyperuricaemia—Doxorubicin—peripheral nervous system neoplasm	0.000386	0.00223	CcSEcCtD
Tolvaptan—Mediastinal disorder—Vincristine—peripheral nervous system neoplasm	0.000386	0.00223	CcSEcCtD
Tolvaptan—Hyperkalaemia—Epirubicin—peripheral nervous system neoplasm	0.00038	0.0022	CcSEcCtD
Tolvaptan—Renal failure—Etoposide—peripheral nervous system neoplasm	0.00038	0.0022	CcSEcCtD
Tolvaptan—Blood bilirubin increased—Doxorubicin—peripheral nervous system neoplasm	0.000379	0.00219	CcSEcCtD
Tolvaptan—Malaise—Dactinomycin—peripheral nervous system neoplasm	0.000376	0.00218	CcSEcCtD
Tolvaptan—Urinary tract disorder—Cisplatin—peripheral nervous system neoplasm	0.000374	0.00216	CcSEcCtD
Tolvaptan—Connective tissue disorder—Cisplatin—peripheral nervous system neoplasm	0.000372	0.00215	CcSEcCtD
Tolvaptan—Urethral disorder—Cisplatin—peripheral nervous system neoplasm	0.000371	0.00215	CcSEcCtD
Tolvaptan—Decreased appetite—Topotecan—peripheral nervous system neoplasm	0.000365	0.00211	CcSEcCtD
Tolvaptan—Blood uric acid increased—Doxorubicin—peripheral nervous system neoplasm	0.000365	0.00211	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Topotecan—peripheral nervous system neoplasm	0.000362	0.0021	CcSEcCtD
Tolvaptan—Decreased appetite—Isotretinoin—peripheral nervous system neoplasm	0.000362	0.00209	CcSEcCtD
Tolvaptan—Decreased appetite—Tretinoin—peripheral nervous system neoplasm	0.000362	0.00209	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Tretinoin—peripheral nervous system neoplasm	0.00036	0.00208	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Isotretinoin—peripheral nervous system neoplasm	0.00036	0.00208	CcSEcCtD
Tolvaptan—Constipation—Topotecan—peripheral nervous system neoplasm	0.000359	0.00208	CcSEcCtD
Tolvaptan—Ill-defined disorder—Alitretinoin—peripheral nervous system neoplasm	0.000359	0.00208	CcSEcCtD
Tolvaptan—Pulmonary embolism—Doxorubicin—peripheral nervous system neoplasm	0.000358	0.00207	CcSEcCtD
Tolvaptan—Decreased appetite—Melphalan—peripheral nervous system neoplasm	0.000357	0.00207	CcSEcCtD
Tolvaptan—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.000356	0.00206	CcSEcCtD
Tolvaptan—Constipation—Tretinoin—peripheral nervous system neoplasm	0.000356	0.00206	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Melphalan—peripheral nervous system neoplasm	0.000355	0.00205	CcSEcCtD
Tolvaptan—Hyperkalaemia—Doxorubicin—peripheral nervous system neoplasm	0.000352	0.00204	CcSEcCtD
Tolvaptan—Cardiac disorder—Cisplatin—peripheral nervous system neoplasm	0.000351	0.00203	CcSEcCtD
Tolvaptan—Discomfort—Dactinomycin—peripheral nervous system neoplasm	0.000351	0.00203	CcSEcCtD
Tolvaptan—Ecchymosis—Epirubicin—peripheral nervous system neoplasm	0.00035	0.00202	CcSEcCtD
Tolvaptan—Malaise—Alitretinoin—peripheral nervous system neoplasm	0.000349	0.00202	CcSEcCtD
Tolvaptan—Syncope—Alitretinoin—peripheral nervous system neoplasm	0.000347	0.00201	CcSEcCtD
Tolvaptan—Feeling abnormal—Topotecan—peripheral nervous system neoplasm	0.000346	0.002	CcSEcCtD
Tolvaptan—Feeling abnormal—Isotretinoin—peripheral nervous system neoplasm	0.000343	0.00198	CcSEcCtD
Tolvaptan—Feeling abnormal—Tretinoin—peripheral nervous system neoplasm	0.000343	0.00198	CcSEcCtD
Tolvaptan—Urinary tract disorder—Etoposide—peripheral nervous system neoplasm	0.000342	0.00198	CcSEcCtD
Tolvaptan—Immune system disorder—Cisplatin—peripheral nervous system neoplasm	0.000342	0.00198	CcSEcCtD
Tolvaptan—Mediastinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000341	0.00197	CcSEcCtD
Tolvaptan—Urethral disorder—Etoposide—peripheral nervous system neoplasm	0.00034	0.00197	CcSEcCtD
Tolvaptan—Loss of consciousness—Alitretinoin—peripheral nervous system neoplasm	0.00034	0.00197	CcSEcCtD
Tolvaptan—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.000332	0.00192	CcSEcCtD
Tolvaptan—Malnutrition—Cisplatin—peripheral nervous system neoplasm	0.000329	0.00191	CcSEcCtD
Tolvaptan—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.000329	0.0019	CcSEcCtD
Tolvaptan—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.000329	0.0019	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Alitretinoin—peripheral nervous system neoplasm	0.000327	0.00189	CcSEcCtD
Tolvaptan—Discomfort—Alitretinoin—peripheral nervous system neoplasm	0.000325	0.00188	CcSEcCtD
Tolvaptan—Anorexia—Dactinomycin—peripheral nervous system neoplasm	0.000324	0.00188	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000324	0.0237	CbGpPWpGaD
Tolvaptan—Ecchymosis—Doxorubicin—peripheral nervous system neoplasm	0.000324	0.00187	CcSEcCtD
Tolvaptan—Dry mouth—Alitretinoin—peripheral nervous system neoplasm	0.000322	0.00186	CcSEcCtD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—NTS—peripheral nervous system neoplasm	0.000322	0.0236	CbGpPWpGaD
Tolvaptan—Cardiac disorder—Etoposide—peripheral nervous system neoplasm	0.000322	0.00186	CcSEcCtD
Tolvaptan—Anaphylactic shock—Alitretinoin—peripheral nervous system neoplasm	0.000316	0.00183	CcSEcCtD
Tolvaptan—Angiopathy—Etoposide—peripheral nervous system neoplasm	0.000315	0.00182	CcSEcCtD
Tolvaptan—Immune system disorder—Etoposide—peripheral nervous system neoplasm	0.000313	0.00181	CcSEcCtD
Tolvaptan—Mediastinal disorder—Etoposide—peripheral nervous system neoplasm	0.000313	0.00181	CcSEcCtD
Tolvaptan—Shock—Alitretinoin—peripheral nervous system neoplasm	0.000311	0.0018	CcSEcCtD
Tolvaptan—Nervous system disorder—Alitretinoin—peripheral nervous system neoplasm	0.00031	0.00179	CcSEcCtD
Tolvaptan—Hypersensitivity—Topotecan—peripheral nervous system neoplasm	0.000309	0.00179	CcSEcCtD
Tolvaptan—Hypersensitivity—Isotretinoin—peripheral nervous system neoplasm	0.000307	0.00177	CcSEcCtD
Tolvaptan—Hypersensitivity—Tretinoin—peripheral nervous system neoplasm	0.000307	0.00177	CcSEcCtD
Tolvaptan—Skin disorder—Alitretinoin—peripheral nervous system neoplasm	0.000307	0.00177	CcSEcCtD
Tolvaptan—Ill-defined disorder—Cisplatin—peripheral nervous system neoplasm	0.000306	0.00177	CcSEcCtD
Tolvaptan—Anaphylactic shock—Vincristine—peripheral nervous system neoplasm	0.000304	0.00176	CcSEcCtD
Tolvaptan—Hypersensitivity—Melphalan—peripheral nervous system neoplasm	0.000303	0.00175	CcSEcCtD
Tolvaptan—Asthenia—Topotecan—peripheral nervous system neoplasm	0.000301	0.00174	CcSEcCtD
Tolvaptan—Anorexia—Alitretinoin—peripheral nervous system neoplasm	0.000301	0.00174	CcSEcCtD
Tolvaptan—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.000299	0.00173	CcSEcCtD
Tolvaptan—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.000299	0.00173	CcSEcCtD
Tolvaptan—Nervous system disorder—Vincristine—peripheral nervous system neoplasm	0.000298	0.00172	CcSEcCtD
Tolvaptan—Malaise—Cisplatin—peripheral nervous system neoplasm	0.000297	0.00172	CcSEcCtD
Tolvaptan—Pruritus—Topotecan—peripheral nervous system neoplasm	0.000297	0.00172	CcSEcCtD
Tolvaptan—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.000296	0.00171	CcSEcCtD
Tolvaptan—Dysgeusia—Etoposide—peripheral nervous system neoplasm	0.000296	0.00171	CcSEcCtD
Tolvaptan—Renal impairment—Epirubicin—peripheral nervous system neoplasm	0.000295	0.00171	CcSEcCtD
Tolvaptan—Asthenia—Melphalan—peripheral nervous system neoplasm	0.000295	0.00171	CcSEcCtD
Tolvaptan—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.000295	0.0017	CcSEcCtD
Tolvaptan—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.000295	0.0017	CcSEcCtD
Tolvaptan—Pruritus—Melphalan—peripheral nervous system neoplasm	0.000291	0.00168	CcSEcCtD
Tolvaptan—Anorexia—Vincristine—peripheral nervous system neoplasm	0.00029	0.00168	CcSEcCtD
Tolvaptan—Hypoglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000288	0.00167	CcSEcCtD
Tolvaptan—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.000287	0.00166	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Epirubicin—peripheral nervous system neoplasm	0.000287	0.00166	CcSEcCtD
Tolvaptan—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.000285	0.00165	CcSEcCtD
Tolvaptan—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.000285	0.00165	CcSEcCtD
Tolvaptan—Hyponatraemia—Epirubicin—peripheral nervous system neoplasm	0.000282	0.00163	CcSEcCtD
Tolvaptan—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.000281	0.00163	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000281	0.00163	CcSEcCtD
Tolvaptan—Feeling abnormal—Dactinomycin—peripheral nervous system neoplasm	0.00028	0.00162	CcSEcCtD
Tolvaptan—Ill-defined disorder—Etoposide—peripheral nervous system neoplasm	0.00028	0.00162	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.000279	0.00161	CcSEcCtD
Tolvaptan—Dizziness—Topotecan—peripheral nervous system neoplasm	0.000278	0.00161	CcSEcCtD
Tolvaptan—Discomfort—Cisplatin—peripheral nervous system neoplasm	0.000277	0.0016	CcSEcCtD
Tolvaptan—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.000275	0.00159	CcSEcCtD
Tolvaptan—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.000275	0.00159	CcSEcCtD
Tolvaptan—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.000274	0.00159	CcSEcCtD
Tolvaptan—CYP3A4—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.000274	0.02	CbGpPWpGaD
Tolvaptan—Renal impairment—Doxorubicin—peripheral nervous system neoplasm	0.000273	0.00158	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.000272	0.00158	CcSEcCtD
Tolvaptan—Malaise—Etoposide—peripheral nervous system neoplasm	0.000272	0.00157	CcSEcCtD
Tolvaptan—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.00027	0.00156	CcSEcCtD
Tolvaptan—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.000269	0.00156	CcSEcCtD
Tolvaptan—Anaphylactic shock—Cisplatin—peripheral nervous system neoplasm	0.000269	0.00156	CcSEcCtD
Tolvaptan—Hypoglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000266	0.00154	CcSEcCtD
Tolvaptan—Loss of consciousness—Etoposide—peripheral nervous system neoplasm	0.000265	0.00153	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Doxorubicin—peripheral nervous system neoplasm	0.000265	0.00153	CcSEcCtD
Tolvaptan—AVPR2—G alpha (s) signalling events—GNAS—peripheral nervous system neoplasm	0.000265	0.0194	CbGpPWpGaD
Tolvaptan—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.000264	0.00153	CcSEcCtD
Tolvaptan—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.000264	0.00153	CcSEcCtD
Tolvaptan—Blood creatinine increased—Epirubicin—peripheral nervous system neoplasm	0.000263	0.00152	CcSEcCtD
Tolvaptan—Headache—Topotecan—peripheral nervous system neoplasm	0.000263	0.00152	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.000263	0.00152	CcSEcCtD
Tolvaptan—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.000261	0.00151	CcSEcCtD
Tolvaptan—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.000261	0.00151	CcSEcCtD
Tolvaptan—Hyponatraemia—Doxorubicin—peripheral nervous system neoplasm	0.000261	0.00151	CcSEcCtD
Tolvaptan—Headache—Isotretinoin—peripheral nervous system neoplasm	0.000261	0.00151	CcSEcCtD
Tolvaptan—Headache—Tretinoin—peripheral nervous system neoplasm	0.000261	0.00151	CcSEcCtD
Tolvaptan—Feeling abnormal—Alitretinoin—peripheral nervous system neoplasm	0.00026	0.0015	CcSEcCtD
Tolvaptan—Constipation—Vincristine—peripheral nervous system neoplasm	0.00026	0.0015	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.00026	0.0015	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Epirubicin—peripheral nervous system neoplasm	0.000257	0.00148	CcSEcCtD
Tolvaptan—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.000256	0.00148	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.000255	0.00148	CcSEcCtD
Tolvaptan—Discomfort—Etoposide—peripheral nervous system neoplasm	0.000254	0.00147	CcSEcCtD
Tolvaptan—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.000254	0.00147	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000253	0.00146	CcSEcCtD
Tolvaptan—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000251	0.00145	CcSEcCtD
Tolvaptan—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000249	0.00144	CcSEcCtD
Tolvaptan—Nausea—Topotecan—peripheral nervous system neoplasm	0.000249	0.00144	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Epirubicin—peripheral nervous system neoplasm	0.000248	0.00143	CcSEcCtD
Tolvaptan—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000247	0.00143	CcSEcCtD
Tolvaptan—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000247	0.00143	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000247	0.0181	CbGpPWpGaD
Tolvaptan—Anaphylactic shock—Etoposide—peripheral nervous system neoplasm	0.000246	0.00142	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—NTS—peripheral nervous system neoplasm	0.000245	0.0179	CbGpPWpGaD
Tolvaptan—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000244	0.00141	CcSEcCtD
Tolvaptan—Nausea—Melphalan—peripheral nervous system neoplasm	0.000244	0.00141	CcSEcCtD
Tolvaptan—Blood creatinine increased—Doxorubicin—peripheral nervous system neoplasm	0.000244	0.00141	CcSEcCtD
Tolvaptan—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.000242	0.0014	CcSEcCtD
Tolvaptan—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.00024	0.00139	CcSEcCtD
Tolvaptan—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000239	0.00138	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Doxorubicin—peripheral nervous system neoplasm	0.000237	0.00137	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000237	0.0173	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—CD55—peripheral nervous system neoplasm	0.000235	0.0172	CbGpPWpGaD
Tolvaptan—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000235	0.00136	CcSEcCtD
Tolvaptan—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000235	0.00136	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000234	0.00135	CcSEcCtD
Tolvaptan—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000234	0.00135	CcSEcCtD
Tolvaptan—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.000233	0.00135	CcSEcCtD
Tolvaptan—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000233	0.00134	CcSEcCtD
Tolvaptan—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.000232	0.017	CbGpPWpGaD
Tolvaptan—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000232	0.00134	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Doxorubicin—peripheral nervous system neoplasm	0.000229	0.00133	CcSEcCtD
Tolvaptan—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000226	0.00131	CcSEcCtD
Tolvaptan—Pollakiuria—Epirubicin—peripheral nervous system neoplasm	0.000224	0.0013	CcSEcCtD
Tolvaptan—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000224	0.0013	CcSEcCtD
Tolvaptan—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000223	0.00129	CcSEcCtD
Tolvaptan—Feeling abnormal—Cisplatin—peripheral nervous system neoplasm	0.000222	0.00128	CcSEcCtD
Tolvaptan—AVPR1A—G alpha (q) signalling events—KNG1—peripheral nervous system neoplasm	0.00022	0.0161	CbGpPWpGaD
Tolvaptan—Hyperglycaemia—Epirubicin—peripheral nervous system neoplasm	0.000219	0.00127	CcSEcCtD
Tolvaptan—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000218	0.00126	CcSEcCtD
Tolvaptan—AVPR1A—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.000217	0.0159	CbGpPWpGaD
Tolvaptan—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000216	0.00125	CcSEcCtD
Tolvaptan—AVPR2—Peptide ligand-binding receptors—KNG1—peripheral nervous system neoplasm	0.000216	0.0158	CbGpPWpGaD
Tolvaptan—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000214	0.00124	CcSEcCtD
Tolvaptan—Renal failure—Epirubicin—peripheral nervous system neoplasm	0.000213	0.00123	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000213	0.00123	CcSEcCtD
Tolvaptan—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.000213	0.00123	CcSEcCtD
Tolvaptan—Constipation—Etoposide—peripheral nervous system neoplasm	0.000211	0.00122	CcSEcCtD
Tolvaptan—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000209	0.00121	CcSEcCtD
Tolvaptan—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000208	0.0012	CcSEcCtD
Tolvaptan—Pollakiuria—Doxorubicin—peripheral nervous system neoplasm	0.000208	0.0012	CcSEcCtD
Tolvaptan—Feeling abnormal—Etoposide—peripheral nervous system neoplasm	0.000203	0.00117	CcSEcCtD
Tolvaptan—Hyperglycaemia—Doxorubicin—peripheral nervous system neoplasm	0.000203	0.00117	CcSEcCtD
Tolvaptan—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000202	0.00117	CcSEcCtD
Tolvaptan—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000201	0.00116	CcSEcCtD
Tolvaptan—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000198	0.00115	CcSEcCtD
Tolvaptan—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000198	0.00114	CcSEcCtD
Tolvaptan—Renal failure—Doxorubicin—peripheral nervous system neoplasm	0.000197	0.00114	CcSEcCtD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—KNG1—peripheral nervous system neoplasm	0.000197	0.0144	CbGpPWpGaD
Tolvaptan—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.000195	0.00113	CcSEcCtD
Tolvaptan—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000193	0.00112	CcSEcCtD
Tolvaptan—Urinary tract disorder—Epirubicin—peripheral nervous system neoplasm	0.000192	0.00111	CcSEcCtD
Tolvaptan—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000191	0.0011	CcSEcCtD
Tolvaptan—Urethral disorder—Epirubicin—peripheral nervous system neoplasm	0.000191	0.0011	CcSEcCtD
Tolvaptan—Headache—Vincristine—peripheral nervous system neoplasm	0.000191	0.0011	CcSEcCtD
Tolvaptan—Vismodegib—ABCB1—peripheral nervous system neoplasm	0.00019	1	CrCbGaD
Tolvaptan—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000187	0.00108	CcSEcCtD
Tolvaptan—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000184	0.00106	CcSEcCtD
Tolvaptan—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000182	0.00105	CcSEcCtD
Tolvaptan—Nausea—Vincristine—peripheral nervous system neoplasm	0.000181	0.00104	CcSEcCtD
Tolvaptan—Cardiac disorder—Epirubicin—peripheral nervous system neoplasm	0.00018	0.00104	CcSEcCtD
Tolvaptan—Urinary tract disorder—Doxorubicin—peripheral nervous system neoplasm	0.000178	0.00103	CcSEcCtD
Tolvaptan—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000177	0.00102	CcSEcCtD
Tolvaptan—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000177	0.00102	CcSEcCtD
Tolvaptan—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000176	0.00102	CcSEcCtD
Tolvaptan—Urethral disorder—Doxorubicin—peripheral nervous system neoplasm	0.000176	0.00102	CcSEcCtD
Tolvaptan—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000176	0.00102	CcSEcCtD
Tolvaptan—Mediastinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000175	0.00101	CcSEcCtD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.000175	0.0128	CbGpPWpGaD
Tolvaptan—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000174	0.00101	CcSEcCtD
Tolvaptan—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000169	0.000979	CcSEcCtD
Tolvaptan—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000169	0.000975	CcSEcCtD
Tolvaptan—Cardiac disorder—Doxorubicin—peripheral nervous system neoplasm	0.000167	0.000965	CcSEcCtD
Tolvaptan—Dysgeusia—Epirubicin—peripheral nervous system neoplasm	0.000166	0.000958	CcSEcCtD
Tolvaptan—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000163	0.000944	CcSEcCtD
Tolvaptan—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000163	0.000942	CcSEcCtD
Tolvaptan—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.00094	CcSEcCtD
Tolvaptan—Mediastinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000162	0.000937	CcSEcCtD
Tolvaptan—Nausea—Cisplatin—peripheral nervous system neoplasm	0.00016	0.000924	CcSEcCtD
Tolvaptan—Ill-defined disorder—Epirubicin—peripheral nervous system neoplasm	0.000157	0.000908	CcSEcCtD
Tolvaptan—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000157	0.000906	CcSEcCtD
Tolvaptan—Headache—Etoposide—peripheral nervous system neoplasm	0.000154	0.000893	CcSEcCtD
Tolvaptan—Dysgeusia—Doxorubicin—peripheral nervous system neoplasm	0.000153	0.000887	CcSEcCtD
Tolvaptan—Malaise—Epirubicin—peripheral nervous system neoplasm	0.000153	0.000883	CcSEcCtD
Tolvaptan—Syncope—Epirubicin—peripheral nervous system neoplasm	0.000152	0.000878	CcSEcCtD
Tolvaptan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.00015	0.011	CbGpPWpGaD
Tolvaptan—Loss of consciousness—Epirubicin—peripheral nervous system neoplasm	0.000149	0.00086	CcSEcCtD
Tolvaptan—Nausea—Etoposide—peripheral nervous system neoplasm	0.000146	0.000846	CcSEcCtD
Tolvaptan—AVPR1A—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000146	0.0107	CbGpPWpGaD
Tolvaptan—Ill-defined disorder—Doxorubicin—peripheral nervous system neoplasm	0.000145	0.00084	CcSEcCtD
Tolvaptan—AVPR2—Class A/1 (Rhodopsin-like receptors)—KNG1—peripheral nervous system neoplasm	0.000145	0.0106	CbGpPWpGaD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000143	0.000827	CcSEcCtD
Tolvaptan—Discomfort—Epirubicin—peripheral nervous system neoplasm	0.000142	0.000823	CcSEcCtD
Tolvaptan—Malaise—Doxorubicin—peripheral nervous system neoplasm	0.000141	0.000817	CcSEcCtD
Tolvaptan—Dry mouth—Epirubicin—peripheral nervous system neoplasm	0.000141	0.000815	CcSEcCtD
Tolvaptan—Syncope—Doxorubicin—peripheral nervous system neoplasm	0.00014	0.000812	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.00014	0.0102	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—NTS—peripheral nervous system neoplasm	0.000138	0.0101	CbGpPWpGaD
Tolvaptan—Anaphylactic shock—Epirubicin—peripheral nervous system neoplasm	0.000138	0.000799	CcSEcCtD
Tolvaptan—Loss of consciousness—Doxorubicin—peripheral nervous system neoplasm	0.000138	0.000796	CcSEcCtD
Tolvaptan—Shock—Epirubicin—peripheral nervous system neoplasm	0.000136	0.000786	CcSEcCtD
Tolvaptan—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000135	0.000783	CcSEcCtD
Tolvaptan—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.000134	0.000776	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000766	CcSEcCtD
Tolvaptan—Discomfort—Doxorubicin—peripheral nervous system neoplasm	0.000132	0.000762	CcSEcCtD
Tolvaptan—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.000132	0.000761	CcSEcCtD
Tolvaptan—Dry mouth—Doxorubicin—peripheral nervous system neoplasm	0.00013	0.000754	CcSEcCtD
Tolvaptan—Anaphylactic shock—Doxorubicin—peripheral nervous system neoplasm	0.000128	0.000739	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000127	0.00928	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—NTS—peripheral nervous system neoplasm	0.000126	0.00921	CbGpPWpGaD
Tolvaptan—Shock—Doxorubicin—peripheral nervous system neoplasm	0.000126	0.000727	CcSEcCtD
Tolvaptan—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000125	0.000725	CcSEcCtD
Tolvaptan—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.000124	0.000718	CcSEcCtD
Tolvaptan—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000122	0.000704	CcSEcCtD
Tolvaptan—AVPR1A—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000121	0.00889	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—CD55—peripheral nervous system neoplasm	0.000121	0.00883	CbGpPWpGaD
Tolvaptan—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.00012	0.000694	CcSEcCtD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—PTPN11—peripheral nervous system neoplasm	0.00012	0.00875	CbGpPWpGaD
Tolvaptan—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000119	0.00069	CcSEcCtD
Tolvaptan—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000118	0.000683	CcSEcCtD
Tolvaptan—Feeling abnormal—Epirubicin—peripheral nervous system neoplasm	0.000114	0.000658	CcSEcCtD
Tolvaptan—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000111	0.000642	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.000111	0.00812	CbGpPWpGaD
Tolvaptan—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.00011	0.000638	CcSEcCtD
Tolvaptan—AVPR2—GPCR ligand binding—KNG1—peripheral nervous system neoplasm	0.00011	0.00806	CbGpPWpGaD
Tolvaptan—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000109	0.000632	CcSEcCtD
Tolvaptan—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000109	0.000631	CcSEcCtD
Tolvaptan—AVPR1A—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000106	0.00774	CbGpPWpGaD
Tolvaptan—Feeling abnormal—Doxorubicin—peripheral nervous system neoplasm	0.000105	0.000609	CcSEcCtD
Tolvaptan—AVPR2—GPCR downstream signaling—VIP—peripheral nervous system neoplasm	0.000105	0.00769	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—peripheral nervous system neoplasm	0.000104	0.00762	CbGpPWpGaD
Tolvaptan—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000102	0.000588	CcSEcCtD
Tolvaptan—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000101	0.000584	CcSEcCtD
Tolvaptan—Asthenia—Epirubicin—peripheral nervous system neoplasm	9.91e-05	0.000573	CcSEcCtD
Tolvaptan—Pruritus—Epirubicin—peripheral nervous system neoplasm	9.77e-05	0.000565	CcSEcCtD
Tolvaptan—AVPR1A—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	9.7e-05	0.0071	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR ligand binding—GNAS—peripheral nervous system neoplasm	9.63e-05	0.00705	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—VIP—peripheral nervous system neoplasm	9.6e-05	0.00703	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—VIP—peripheral nervous system neoplasm	9.53e-05	0.00698	CbGpPWpGaD
Tolvaptan—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	9.45e-05	0.000546	CcSEcCtD
Tolvaptan—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	9.41e-05	0.000544	CcSEcCtD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	9.26e-05	0.00678	CbGpPWpGaD
Tolvaptan—Asthenia—Doxorubicin—peripheral nervous system neoplasm	9.17e-05	0.00053	CcSEcCtD
Tolvaptan—Dizziness—Epirubicin—peripheral nervous system neoplasm	9.13e-05	0.000528	CcSEcCtD
Tolvaptan—Pruritus—Doxorubicin—peripheral nervous system neoplasm	9.04e-05	0.000523	CcSEcCtD
Tolvaptan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	9.03e-05	0.00661	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	8.86e-05	0.00649	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—PPP3R1—peripheral nervous system neoplasm	8.8e-05	0.00644	CbGpPWpGaD
Tolvaptan—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	8.74e-05	0.000506	CcSEcCtD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	8.73e-05	0.00639	CbGpPWpGaD
Tolvaptan—Headache—Epirubicin—peripheral nervous system neoplasm	8.65e-05	0.0005	CcSEcCtD
Tolvaptan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	8.6e-05	0.0063	CbGpPWpGaD
Tolvaptan—Dizziness—Doxorubicin—peripheral nervous system neoplasm	8.45e-05	0.000489	CcSEcCtD
Tolvaptan—Nausea—Epirubicin—peripheral nervous system neoplasm	8.2e-05	0.000474	CcSEcCtD
Tolvaptan—Headache—Doxorubicin—peripheral nervous system neoplasm	8e-05	0.000463	CcSEcCtD
Tolvaptan—Nausea—Doxorubicin—peripheral nervous system neoplasm	7.59e-05	0.000439	CcSEcCtD
Tolvaptan—AVPR1A—Signaling Pathways—NTS—peripheral nervous system neoplasm	7.48e-05	0.00548	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	7.45e-05	0.00546	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—NTS—peripheral nervous system neoplasm	7.43e-05	0.00544	CbGpPWpGaD
Tolvaptan—AVPR2—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	7.31e-05	0.00536	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—peripheral nervous system neoplasm	7.19e-05	0.00526	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CD55—peripheral nervous system neoplasm	7.17e-05	0.00525	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CD55—peripheral nervous system neoplasm	7.12e-05	0.00522	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.27e-05	0.00459	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—KNG1—peripheral nervous system neoplasm	6.22e-05	0.00456	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	5.69e-05	0.00417	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.67e-05	0.00415	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—KNG1—peripheral nervous system neoplasm	5.65e-05	0.00414	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—VIP—peripheral nervous system neoplasm	5.63e-05	0.00412	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.48e-05	0.00401	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—GNAS—peripheral nervous system neoplasm	5.44e-05	0.00398	CbGpPWpGaD
Tolvaptan—AVPR1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—peripheral nervous system neoplasm	5.26e-05	0.00385	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.23e-05	0.00383	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	5.2e-05	0.00381	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.98e-05	0.00364	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—GNAS—peripheral nervous system neoplasm	4.94e-05	0.00362	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	4.28e-05	0.00313	CbGpPWpGaD
Tolvaptan—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—peripheral nervous system neoplasm	4.13e-05	0.00303	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.93e-05	0.00288	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	3.9e-05	0.00286	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	3.9e-05	0.00285	CbGpPWpGaD
Tolvaptan—ABCB1—Allograft Rejection—CASP3—peripheral nervous system neoplasm	3.61e-05	0.00265	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	3.57e-05	0.00261	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	3.47e-05	0.00254	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.46e-05	0.00253	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—PTPN11—peripheral nervous system neoplasm	3.43e-05	0.00251	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.36e-05	0.00246	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—KNG1—peripheral nervous system neoplasm	3.34e-05	0.00244	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	3.34e-05	0.00244	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.2e-05	0.00235	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	3.18e-05	0.00233	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.94e-05	0.00215	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—GNAS—peripheral nervous system neoplasm	2.92e-05	0.00214	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—HSD17B12—peripheral nervous system neoplasm	2.34e-05	0.00171	CbGpPWpGaD
Tolvaptan—ABCB1—HIF-1-alpha transcription factor network—AKT1—peripheral nervous system neoplasm	2.26e-05	0.00165	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	2.14e-05	0.00156	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.08e-05	0.00152	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—NRAS—peripheral nervous system neoplasm	2.06e-05	0.00151	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.04e-05	0.0015	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	2.03e-05	0.00149	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	1.96e-05	0.00144	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	1.78e-05	0.00131	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	1.76e-05	0.00129	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GNS—peripheral nervous system neoplasm	1.69e-05	0.00124	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—NME1—peripheral nervous system neoplasm	1.62e-05	0.00119	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.61e-05	0.00118	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	1.6e-05	0.00117	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—COX2—peripheral nervous system neoplasm	1.56e-05	0.00114	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.52e-05	0.00111	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—HRAS—peripheral nervous system neoplasm	1.51e-05	0.00111	CbGpPWpGaD
Tolvaptan—AVPR1A—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.48e-05	0.00108	CbGpPWpGaD
Tolvaptan—AVPR2—GPCR downstream signaling—AKT1—peripheral nervous system neoplasm	1.47e-05	0.00108	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.47e-05	0.00107	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—CASP3—peripheral nervous system neoplasm	1.46e-05	0.00107	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	1.44e-05	0.00106	CbGpPWpGaD
Tolvaptan—ABCB1—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	1.42e-05	0.00104	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	1.39e-05	0.00102	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.34e-05	0.000984	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling by GPCR—AKT1—peripheral nervous system neoplasm	1.33e-05	0.000977	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.23e-05	0.0009	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—NRAS—peripheral nervous system neoplasm	1.22e-05	0.000893	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.14e-05	0.000838	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	1.14e-05	0.000837	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—MYC—peripheral nervous system neoplasm	1.14e-05	0.000832	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	1.04e-05	0.000764	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—ENO2—peripheral nervous system neoplasm	1.03e-05	0.000751	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	1e-05	0.000732	CbGpPWpGaD
Tolvaptan—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	9.65e-06	0.000707	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	9.62e-06	0.000705	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.4e-06	0.000688	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—TP53—peripheral nervous system neoplasm	9.33e-06	0.000683	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.99e-06	0.000658	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—HRAS—peripheral nervous system neoplasm	8.92e-06	0.000653	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—BCHE—peripheral nervous system neoplasm	8.66e-06	0.000634	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—SLC2A1—peripheral nervous system neoplasm	8.27e-06	0.000605	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—TH—peripheral nervous system neoplasm	8.15e-06	0.000597	CbGpPWpGaD
Tolvaptan—AVPR1A—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.94e-06	0.000581	CbGpPWpGaD
Tolvaptan—AVPR2—Signaling Pathways—AKT1—peripheral nervous system neoplasm	7.88e-06	0.000577	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—GNAS—peripheral nervous system neoplasm	6.65e-06	0.000487	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	6.32e-06	0.000463	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	5.34e-06	0.000391	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	5.09e-06	0.000373	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	5.02e-06	0.000368	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	4.1e-06	0.0003	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	4.02e-06	0.000294	CbGpPWpGaD
Tolvaptan—ABCB1—Metabolism—AKT1—peripheral nervous system neoplasm	1.8e-06	0.000131	CbGpPWpGaD
Tolvaptan—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	1.11e-06	8.1e-05	CbGpPWpGaD
